



What is claimed is:

1. A compound of the formula:




(I)

OR



(II)

OR




(III)

15


OR

110




(IV)

OR



(V)


OR



10

(VI)

OR




15

(VII)

OR

111



(VIII)

wherein:

5 R<sup>1</sup> is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

10 R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, I, CH<sub>3</sub>, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CF<sub>2</sub>Cl, CN, CF<sub>2</sub>OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl and alkynyl groups may be optionally substituted;

15 R<sup>3</sup> through R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups may be optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted; or

20 R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I, CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and arylalkyl groups may be optionally substituted;

5 R<sup>11</sup> is selected from the group of hydrogen, F, Br, Cl, I, CN, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, SR<sup>14</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>, SOR<sup>14</sup> and SO<sub>2</sub>R<sup>14</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

10 R<sup>12</sup> and R<sup>13</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted;

15 R<sup>14</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups may be optionally substituted;

R<sup>15</sup> and R<sup>16</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

W is O or S;

20 X is selected from the group of O, S and N{R<sup>14</sup>};

Y is selected from the group of O, S, N{R<sup>12</sup>}, NO{R<sup>12</sup>} and CR<sup>12</sup>R<sup>13</sup>;

Z is selected from the group of O, S and N{R<sup>12</sup>};

n is 0, 1 or 2;

m is 0, 1, or 2;

25 and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub>

heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

3. A compound according to claim 1, wherein R<sup>2</sup> is selected from the group of  
5 CF<sub>2</sub>OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup> and NR<sup>12</sup>R<sup>13</sup>.

4. A compound according to claim 1, wherein R<sup>2</sup> is selected from the group of  
hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub>  
10 heteroalkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl and C<sub>2</sub>-C<sub>4</sub> alkynyl, wherein the alkyl, haloalkyl, heteroalkyl,  
alkenyl and alkynyl groups may be optionally substituted.

5. A compound according to claim 4, wherein R<sup>2</sup> is selected from the group of  
hydrogen, F, Cl, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub> and optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl.

15 6. A compound according to claim 1, wherein R<sup>9</sup> and R<sup>10</sup> each independently is  
selected from hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl,  
wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted

20 7. A compound according to claim 6, wherein R<sup>9</sup> and R<sup>10</sup> each independently is  
selected from the group of hydrogen, F, Cl, C<sub>1</sub> - C<sub>4</sub> alkyl, C<sub>1</sub> - C<sub>4</sub> haloalkyl and C<sub>1</sub> - C<sub>4</sub>  
heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally  
substituted.

25 8. A compound according to claim 7, wherein R<sup>9</sup> and R<sup>10</sup> each independently is  
selected from the group of hydrogen, F and CH<sub>3</sub>.

9. A compound according to claim 1, wherein R<sup>1</sup> is selected from the group of hydrogen, F, Cl, Br, I, C<sub>1</sub> – C<sub>6</sub> alkyl, C<sub>1</sub> – C<sub>6</sub> haloalkyl and C<sub>1</sub> – C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

5 10. A compound according to claim 9, wherein R<sup>1</sup> is selected from the group of hydrogen, F, Cl, C<sub>1</sub> – C<sub>4</sub> alkyl, C<sub>1</sub> – C<sub>4</sub> haloalkyl and C<sub>1</sub> – C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

11. A compound according to claim 9, wherein R<sup>1</sup> is hydrogen or F.

10 12. A compound according to claim 1, wherein Y and W each independently is O or S.

13. A compound according to claim 12, wherein Y and W are each O.

15 14. A compound according to claim 1, wherein R<sup>11</sup> is selected from the group of hydrogen, F, Br, Cl, CN, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, SR<sup>14</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>, SOR<sup>14</sup> and SO<sub>2</sub>R<sup>14</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

20 15. A compound according to claim 14, wherein R<sup>11</sup> is selected from the group of hydrogen, F, Cl, OR<sup>14</sup>, SR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>, SOR<sup>14</sup>, SO<sub>2</sub>R<sup>14</sup> and optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl.

25 16. A compound according to claim 15, wherein R<sup>11</sup> is selected from the group of hydrogen, F, Cl, OR<sup>14</sup> and SR<sup>14</sup>.

17. A compound according to claim 16, wherein R<sup>11</sup> is OR<sup>14</sup>.

18. A compound according to claim 1, wherein Z is O or N{R<sup>12</sup>}.

19. A compound according to claim 18, wherein Z is N{R<sup>12</sup>}.

5

20. A compound according to claim 18, wherein Z is O.

21. A compound according to claim 1, wherein n is 0 or 1.

10 22. A compound according to claim 21, wherein n is 0.

15 23. A compound according to claim 1, wherein R<sup>12</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

20 24. A compound according to claim 23, wherein R<sup>12</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

25

25 25. A compound according to claim 1, wherein R<sup>13</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

25

26. A compound according to claim 25, wherein R<sup>13</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

27. A compound according to claim 1, wherein X is O or N{R<sup>14</sup>}.

28. A compound according to claim 27, wherein X is N{R<sup>14</sup>}.

5

29. A compound according to claim 28, wherein X is NH.

30. A compound according to claim 1, wherein R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

15

31. A compound according to claim 30, wherein R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

20

32. A compound according to claim 1, wherein R<sup>5</sup> and R<sup>7</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or R<sup>5</sup> and R<sup>7</sup> taken together form a bond.

25

33. A compound according to claim 32, wherein R<sup>5</sup> and R<sup>7</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

34. A compound according to claim 1, wherein R<sup>6</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups may be optionally substituted; or

5 R<sup>6</sup> and R<sup>8</sup> taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

10 35. A compound according to claim 34, wherein R<sup>6</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, C<sub>1</sub> – C<sub>4</sub> alkyl, C<sub>1</sub> – C<sub>4</sub> haloalkyl, C<sub>1</sub> – C<sub>4</sub> heteroalkyl, heteroaryl and aryl, wherein alkyl, haloalkyl, heteroaryl and aryl may be optionally substituted; or

15 R<sup>6</sup> and R<sup>8</sup> taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

36. A compound according to claim 1, wherein:

20 R<sup>1</sup> is selected from the group of hydrogen, F, Cl, Br, I, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; and

25 R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

37. A compound according to claim 36, wherein:

**R<sup>5</sup>** through **R<sup>8</sup>** each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

**R<sup>6</sup>** and **R<sup>8</sup>** taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

38. A compound according to claim 37, wherein:

**R<sup>9</sup>** and **R<sup>10</sup>** each independently is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

**R<sup>12</sup>** is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted; and

**R<sup>14</sup>** is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

39. A compound according to claim 38, wherein:

W is O or S;

X is O or N{R<sup>14</sup>};

Y is O or S;

Z is O or N{R<sup>12</sup>}; and

n is 0 or 1.

40. A compound according to claim 1, wherein said compound is selected from the group of:

5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;

5,6,7,8-Tetrahydro-7,7-diethyl-4-trifluoromethylpyridino[3,2-*f*]quinolin-2(1*H*)-one;  
7,8-Dihydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-*f*]quinolin-2(1*H*)-one;  
5,6,7,8-Tetrahydro-7,7,8-trimethyl-4-trifluoromethylpyridino[3,2-*f*]quinolin-2(1*H*)-one;  
8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-*f*]quinolin-2(1*H*)-one;  
5 5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-*f*]quinolin-2(1*H*)-one;  
8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethyl-pyridino[3,2-*f*]quinolin-2(1*H*)-one;  
6-Hydrazino-4-trifluoromethylquinolin-2(1*H*)-one;  
6-Methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Isopropyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Allyl-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-(4-Methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
4-Trifluoromethyl-5,6,7,8-tetrahydrocyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
4-Trifluoromethyl-5,6,7,8,9,10-hexahydrocycloheptano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
20 ( $\pm$ )-6,6a,7,8,9,9a(*cis*)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;  
( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
( $\pm$ )-6,6a,7,8,9,9a(*cis*)-Hexahydro-6-ethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;  
25 ( $\pm$ )-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[*g*]pyrrolo-[3,2-*f*]quinolin-2(1*H*)-one;

5 ( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(3-furanylmethyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(3-thiophenemethyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

10 ( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2-methylpropyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

15 ( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-4*c*,5,6,7,7*a*(*cis*),8-Hexahydro-8-(2,2-dimethoxyethyl)-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

20 ( $\pm$ )-4*c*,5,6,7,8,8*a*(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-4*c*,5,6,7,8,9,9*a*(*cis*),10-Octahydro-10-(2,2,2-trifluoroethyl)-4-trifluoromethylcycloheptano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

25 ( $\pm$ )-5,6- *cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-nitrophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-dimethylaminophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5 ( $\pm$ )-5,6- *cis*-Dihydro-5-(3-trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

10 ( $\pm$ )-5,6-Dihydro-5-phenyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-(4-methoxyphenyl)-6-methyl-7-(2,2-dimethoxyethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

15 ( $\pm$ )-5,6- *cis*-Dihydro-5-isopropyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

20 ( $\pm$ )-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6-Dihydro-5-(2-ethoxycarbonylethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

25 6-Ethyl-5-methyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-  
one;  
5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-  
one;  
5-Ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-  
one;  
5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-  
2(1*H*)-one;  
10 8-Trifluoroethyl-4-trifluoromethyl-6,8-dihydrocyclopentano[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-  
one;  
9-Trifluoroethyl-4-trifluoromethyl-9*H*-benzo[*g*]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[*i*]pyrrolo[2,3-*g*]quinolin-  
2(1*H*)-one;  
15 5-(3-Trifluoromethylphenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-  
pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-(4-Fluorophenyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
20 5-(2-Ethoxycarbonylethyl)-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-  
pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-  
one;  
25 5-Hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Methyl-6-(1-hydroxyethyl)-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;  
5-Methyl-6-acetyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Formyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Acetyloxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5 2-Acetyloxy-5-hydroxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinoline;

6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5-Ethoxymethyl-6-ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

10 6-(1-Methoxyethyl)-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

7-Allyl-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

6-Ethyl-7-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

7-(3-Trifluoromethylphenyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

15 7-(2-Hydroxyethyl)-6-methyl-4-trifluoromethyl-5*H*-pyrrolo[2,3-*f*]quinolin-2(1*H*)-one;

(+)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(-)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

20 4-Trifluoromethyl-6,7-dihydro-7,7,9-trimethyl-pyrido[2,3-*g*]quinolin-2(1*H*)-one;

8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-*f*]quinolin-2(1*H*)-one;

4,5,7-Tri(trifluoromethyl)pyrido[3,2-*f*]quinolin-2(1*H*)-one;

5,7-Bis(trifluoromethyl)pyrido[3,2-*f*]quinolin-2(1*H*)-one;

25 4-Trifluoromethyl-7-methyl-6,7,8,9-tetrahydropyrido[2,3-*g*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-7,8-dihydro-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-5,6,7,8-terahydropyrido[2,3-*g*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-7-methyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-*g*]quinolin-2(1*H*)-one;

4-Trifluoromethyl-7-methyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
4-Trifluoromethyl-7-methyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
5 4-Trifluoromethyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
4-Trifluoromethyl-6-propyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
4-Trifluoromethyl-6-ethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
4-Trifluoromethyl-6-cyclopropylmethyl-6,7,8,9-tetrahydropyrido[2,3-g]quinolin-2(1H)-one;  
10 6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
6,7-Dihydro-8,8,10-trimethyl-4-(trifluoromethyl)-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
(±)-6,7-Dihydro-6-ethyl-4-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one  
(±)-7,8-Dihydro-8-ethyl-4-methyl-6H-pyrano[2,3-f]quinolin-2(1H)-one;  
(±)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
15 (-)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
(+)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
(±)-6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
(±)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
20 (±)-6,7-Dihydro-6-ethyl-3-fluoro-4-trifluoromethyl-1-methyl-8H-pyrano[3,2-g]quinolin-2(1H)-one;  
(±)-6,7-Dihydro-6-ethyl-2,4-bis(trifluoromethyl)-8H-pyrano[3,2-g]quinoline;  
6,8,8-Trimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;  
6-Ethyl-8,8-dimethyl-4-trifluoromethyl-8H-pyrano[3,2-g]coumarin;  
25 (±)-5,6-Dihydro-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;  
(±)-5,6-Dihydro-7-ethyl-6-hydroxymethyl-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;  
7,8-Dihydro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;  
6-(2,2,2-Trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;

8-Chloro-6-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[2,3-g]quinolin-2(1H)-one;  
5-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethylpyrrolo[3,2-f]quinolin-2(1H)-one;  
6-Formyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one; and

5 5,6-Dimethyl-7-(2,2-difluorovinyl)-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one.

41. A compound according to claim 1, wherein said compound is selected from the group of:

8-Ethyl-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethylpyridino[3,2-f]quinolin-2(1H)-one;  
5,6,7,8-Tetrahydro-7,7-dimethyl-4-trifluoromethyl-8-propylpyridino[3,2-f]quinolin-2(1H)-one;

8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-7,7-dimethyl-4-trifluoromethyl-pyridino[3,2-f]quinolin-2(1H)-one;

( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;

( $\pm$ )-6,6a,7,8,9,9a(*cis*)-Hexahydro-6-trifluoroethyl-4-trifluoromethylcyclopentano-[i]pyrrolo[2,3-g]quinolin-2(1H)-one;

( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-ethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-f]quinolin-2(1H)-one;

20 ( $\pm$ )-5,6-Dihydro-5,6-*cis*-dimethyl-7-trifluoroethyl-4-trifluoromethyl-7H-pyrrolo[3,2-f]quinolin-2(1H)-one;

( $\pm$ )-7,8-Dihydro-7,8-*cis*-dimethyl-6-trifluoroethyl-4-trifluoromethyl-6H-pyrrolo[2,3-g]quinolin-2(1H)-one;

25 ( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-propyl-4-trifluoromethylcyclopentano-[g]pyrrolo-[3,2-f]quinolin-2(1H)-one;

( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-(2,2,2-chlorodifluoroethyl)-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-f]quinolin-2(1H)-one;

( $\pm$ )-4c,5,6,7,7a(*cis*),8-Hexahydro-8-cyclopropylmethyl-4-trifluoromethyl-cyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-4c,5,6,7,8,8a(*cis*)-Hexahydro-9-(2,2,2-trifluoroethyl)-4-trifluoromethyl-9*H*-cyclohexano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5 ( $\pm$ )-5,6- *cis*-Dihydro-6-ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6- *cis*-Dihydro-5-butyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

10 ( $\pm$ )-5,6-Dihydro-5-ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6-Dihydro-5-ethyl-6-propyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

( $\pm$ )-5,6-*cis*-Dihydro-5-methyl-6-ethyl-7-(2,2,2-trifluoroethyl)-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

15 5,6-Dimethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Ethyl-5-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

20 5-Ethyl-6-methyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

5,6,7,8-Tetrahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

6-Trifluoroethyl-4-trifluoromethyl-6,7,8,9-tetrahydrocyclopentano[i]pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;

25 7-Ethyl-8-methyl-6-(2,2,2-trifluoroethyl)-4-trifluoromethyl-6*H*-pyrrolo[2,3-*g*]quinolin-2(1*H*)-one;


6-Ethyl-7-(2,2,2-trifluoroethyl)-4-trifluoromethyl-7*H*-pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(+)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;

(-)-4c,5,6,7,7a(*cis*),8-Hexahydro-8-trifluoroethyl-4-trifluoromethylcyclopentano-[g]pyrrolo[3,2-*f*]quinolin-2(1*H*)-one;


5 8-(2,2,2-Trifluoroethyl)-5,6,7,8-tetrahydro-5,7,7-trimethylpyrido[3,2-*f*]quinolin-2(1*H*)-one;  
4-Trifluoromethyl-7-methyl-6-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydropyrido[2,3-*g*]quinolin-2(1*H*)-one;  
6,7-Dihydro-8,8-dimethyl-4-(trifluoromethyl)-8*H*-pyrano[3,2-*g*]quinolin-2(1*H*)-one;  
(-)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8*H*-pyrano[3,2-*g*]quinolin-2(1*H*)-one; and  
10 (+)-6,7-Dihydro-6-ethyl-4-trifluoromethyl-8*H*-pyrano[3,2-*g*]quinolin-2(1*H*)-one.

42. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:




(I)

OR




(II)

OR




(III)

OR




(IV)

OR




(V)

OR




(VI)

OR



(VII)

OR



(VIII)

wherein:

R<sup>1</sup> is selected from the group of hydrogen, F, Cl, Br, I, NO<sub>2</sub>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl and C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, I, CH<sub>3</sub>, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CF<sub>2</sub>Cl,  
5 CN, CF<sub>2</sub>OR<sup>12</sup>, CH<sub>2</sub>OR<sup>12</sup>, OR<sup>12</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl,  
C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl and C<sub>2</sub>-C<sub>8</sub> alkynyl, wherein the alkyl, haloalkyl, heteroalkyl,  
alkenyl and alkynyl groups may be optionally substituted;

R<sup>3</sup> through R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I,  
OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub>  
10 alkynyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, aryl, heteroaryl and arylalkyl, wherein the alkyl, haloalkyl,  
heteroalkyl, alkynyl, alkenyl, aryl, heteroaryl and arylalkyl groups may be optionally  
substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>5</sup> and R<sup>7</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a three- to eight-membered saturated or unsaturated  
carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally  
substituted; or

R<sup>6</sup> and R<sup>8</sup> taken together form a three- to eight-membered saturated or unsaturated  
carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may optionally  
20 substituted;

R<sup>9</sup> and R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, I,  
CN, OR<sup>12</sup>, NR<sup>12</sup>R<sup>13</sup>, C<sub>m</sub>(R<sup>12</sup>)<sub>2m</sub>OR<sup>13</sup>, SR<sup>12</sup>, SOR<sup>12</sup>, SO<sub>2</sub>R<sup>12</sup>, NR<sup>12</sup>C(O)R<sup>13</sup>, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub>  
haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl and arylalkyl, wherein the alkyl, haloalkyl, heteroalkyl and  
arylalkyl groups may be optionally substituted;

25 R<sup>11</sup> is selected from the group of hydrogen, F, Br, Cl, I, CN, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub>  
haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, SR<sup>14</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>,  
SOR<sup>14</sup> and SO<sub>2</sub>R<sup>14</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally  
substituted;

R<sup>12</sup> and R<sup>13</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, C<sub>2</sub>-C<sub>8</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted;

5 R<sup>14</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, aryl, heteroaryl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl, heteroalkyl, aryl and heteroaryl groups may be optionally substituted;

10 R<sup>15</sup> and R<sup>16</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

15 W is O or S;

X is selected from the group of O, S and N{R<sup>14</sup>};

Y is selected from the group of O, S, N{R<sup>12</sup>}, N{OR<sup>12</sup>} and CR<sup>12</sup>R<sup>13</sup>;

Z is selected from the group of O, S and N{R<sup>12</sup>};

20 n is 0, 1 or 2;

m is 0, 1, or 2;

and pharmaceutically acceptable salts thereof.

43. A pharmaceutical composition according to claim 42, wherein the carrier is  
20 suitable for enteral, parenteral, suppository, or topical administration.

44. A pharmaceutical composition according to claim 42, wherein R<sup>1</sup> is selected  
from the group of hydrogen, F, Cl, Br, I, C<sub>1</sub> - C<sub>6</sub> alkyl, C<sub>1</sub> - C<sub>6</sub> haloalkyl and C<sub>1</sub> - C<sub>6</sub>  
25 heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally  
substituted.

45. A pharmaceutical composition according to claim 44, wherein R<sup>1</sup> is selected from the group of hydrogen, F, Cl, C<sub>1</sub> – C<sub>4</sub> alkyl, C<sub>1</sub> – C<sub>4</sub> haloalkyl and C<sub>1</sub> – C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

5 46. A pharmaceutical composition according to claim 42, wherein R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

10 47. A pharmaceutical composition according to claim 46, wherein R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

15 48. A pharmaceutical composition according to claim 42, wherein R<sup>9</sup> and R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub> – C<sub>6</sub> alkyl, C<sub>1</sub> – C<sub>6</sub> haloalkyl and C<sub>1</sub> – C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

20 49. A pharmaceutical composition according to claim 48, wherein R<sup>9</sup> and R<sup>10</sup> each independently is selected from the group of hydrogen, F and CH<sub>3</sub>.

50. A pharmaceutical composition according to claim 42, wherein R<sup>11</sup> is selected from the group of hydrogen, F, Br, Cl, CN, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, 25 OR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, SR<sup>14</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>, SOR<sup>14</sup> and SO<sub>2</sub>R<sup>14</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

51. A pharmaceutical composition according to claim 50, wherein R<sup>11</sup> is selected from the group of hydrogen, F, Cl, OR<sup>14</sup>, SR<sup>14</sup>, NR<sup>14</sup>R<sup>13</sup>, CH<sub>2</sub>R<sup>14</sup>, C(O)R<sup>14</sup>, CO<sub>2</sub>R<sup>14</sup>, C(O)NR<sup>14</sup>R<sup>13</sup>, SOR<sup>14</sup>, SO<sub>2</sub>R<sup>14</sup> and optionally substituted C<sub>1</sub>-C<sub>4</sub> alkyl.

5 52. A pharmaceutical composition according to claim 42, wherein Y and W each independently is O or S.

10 53. A pharmaceutical composition according to claim 42, wherein Z is O or N{R<sup>12</sup>}.

15 54. A pharmaceutical composition according to claim 42, wherein n is 0.

55. A pharmaceutical composition according to claim 42, wherein R<sup>12</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted.

20 56. A pharmaceutical composition according to claim 42, wherein X is O or N{R<sup>14</sup>}.

25 57. A pharmaceutical composition according to claim 42, wherein R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

R<sup>3</sup> and R<sup>5</sup> taken together form a bond; or

R<sup>4</sup> and R<sup>6</sup> taken together form a four to six membered carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

58. A pharmaceutical composition according to claim 42, wherein R<sup>5</sup> and R<sup>7</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

5 R<sup>5</sup> and R<sup>7</sup> taken together form a bond.

59. A pharmaceutical composition according to claim 42, wherein R<sup>6</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, heteroaryl and aryl groups may be optionally substituted; or

10 R<sup>6</sup> and R<sup>8</sup> taken together form a three to eight membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

15 60. A pharmaceutical composition according to claim 42, wherein:

R<sup>1</sup> is selected from the group of hydrogen, F, Cl, Br, I, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

20 R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, CF<sub>3</sub>, CF<sub>2</sub>Cl, CF<sub>2</sub>H, CFH<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; and

25 R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

61. A pharmaceutical composition according to claim 60, wherein:

R<sup>5</sup> through R<sup>8</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted; or

5 R<sup>6</sup> and R<sup>8</sup> taken together form a four to six membered saturated or unsaturated carbocyclic or heterocyclic ring, wherein the carbocyclic or heterocyclic ring may be optionally substituted.

62. A pharmaceutical composition according to claim 61, wherein:

10 R<sup>9</sup> and R<sup>10</sup> each independently is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted;

15 R<sup>12</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, heteroaryl and aryl, wherein the alkyl, haloalkyl, heteroalkyl, alkenyl, alkynyl, heteroaryl and aryl groups may be optionally substituted; and

15 R<sup>14</sup> is selected from the group of hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl, C<sub>1</sub>-C<sub>6</sub> heteroalkyl, C(O)R<sup>15</sup>, CO<sub>2</sub>R<sup>15</sup> and C(O)NR<sup>15</sup>R<sup>16</sup>, wherein the alkyl, haloalkyl and heteroalkyl groups may be optionally substituted.

63. A pharmaceutical composition according to claim 62, wherein:

20 W is O or S;

X is O or N{R<sup>14</sup>};

Y is O or S;

Z is O or N{R<sup>12</sup>}; and

n is 0 or 1.

25

64. A method of treating an individual having a condition mediated by an androgen receptor comprising administering to said individual a pharmaceutically effective amount of a compound according to any one of claims 1, 40 or 41.

65. A method according to claim 64, wherein said compound is represented by formula (I).

5 66. A method according to claim 64, wherein said compound is represented by formula (II).

10 67. A method according to claim 64, wherein said compound is represented by formula (III).

15 68. A method according to claim 64, wherein said compound is represented by formula (IV).

69. A method according to claim 64, wherein said compound is represented by formula (V).

70. A method according to claim 64, wherein said compound is represented by formula (VI).

20 71. A method according to claim 64, wherein said compound is represented by formula (VII).

72. A method according to claim 64, wherein said compound is represented by formula (VIII).

25 73. A method according to claim 64, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases,

hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

74. A method according to claim 64, wherein said condition is alleviated with a  
5 therapy selected from the group of male hormone replacement therapy, female androgen  
replacement therapy and stimulation of hematopoiesis.

75. A method of modulating an androgen receptor in an individual comprising  
10 administering an androgen receptor modulating effective amount of a compound according to  
any one of claims 1, 40 or 41.

76. A method according to claim 64, wherein said individual has a condition  
mediated by an androgen receptor

77. A method according to claim 76, wherein said condition is selected from the  
15 group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases,  
hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-  
dependent cancers.

20 78. A method according to claim 76, wherein said condition is alleviated with a  
therapy selected from the group of male hormone replacement therapy, female androgen  
replacement therapy and stimulation of hematopoiesis.

79. A method according to claim 75, wherein said modulation is activation.

25 80. A method according to claim 76, wherein said individual has a condition  
mediated by an androgen receptor.

81. A method according to claim 80, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

5

82. A method according to claim 80, wherein said condition is alleviated with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

10

83. A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 100 nM.

15

84. A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 50 nM.

15

85. A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 20 nM.

20

86. A method according to claim 79, wherein said compound provides 50% maximal activation of AR at a drug concentration of less than 10 nM.

87. A method according to claim 75, wherein said modulation is inhibition.

25

88. A method according to claim 87, wherein said individual has a condition mediated by an androgen receptor.

89. A method according to claim 88, wherein said condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases,

hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.

90. A method according to claim 88, wherein said condition is alleviated with a

5 therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.

91. A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 100 nM.

10 92. A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 50 nM.

15 93. A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 20 nM.

94. A method according to claim 87, wherein said compound provides 50% maximal inhibition of AR at a drug concentration of less than 10 nM.

20 95. A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1, 40 or 41.

96. A method of determining the presence of an androgen receptor (AR) in a cell or cell extract comprising: (a) labeling a compound according to any one of claims 1, 40 or 25 41; (b) contacting the cell or cell extract with said labeled compound; and (c) testing the contacted cell or cell extract to determine the presence of AR.

97. A method for purifying a sample containing an androgen receptor *in vitro*, comprising: (a) contacting said sample with a compound according to any one of claims 1, 40 or 41; (b) allowing said compound to bind to said androgen receptor to form a bound compound/receptor combination; and (c) isolating said bound compound/receptor combination.